

# Clara Natoli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1098345/clara-natoli-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156  
papers

3,708  
citations

30  
h-index

53  
g-index

164  
ext. papers

4,252  
ext. citations

5.3  
avg. IF

4.43  
L-index

#	Paper	IF	Citations
156	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211059873	5.4	1
155	Tgf- $\beta$ transcriptionally promotes 90K expression: possible implications for cancer progression. <i>Cell Death Discovery</i> , <b>2021</b> , 7, 86	6.9	2
154	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
153	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	1
152	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 489-497	2.3	3
151	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 279	12.8	12
150	Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib. <i>International Medical Case Reports Journal</i> , <b>2020</b> , 13, 89-93	1	1
149	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , <b>2020</b> , 128, 17-26	7.5	41
148	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , <b>2020</b> , 235, 7900-7910	7	11
147	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , <b>2020</b> , 12, 59-67	1.8	8
146	Predictive Ability for Disease-Free Survival of the GGrade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. <i>Current Urology</i> , <b>2020</b> , 14, 98-104	1.7	1
145	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920942378	5.4	22
144	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , <b>2020</b> , 15, 228-237	2.4	
143	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1917-1929	7.5	3
142	Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. <i>Recenti Progressi in Medicina</i> , <b>2020</b> , 111, 761-768	0.7	
141	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919853192	5.4	1
140	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable <b>2019</b> , 7, 57		155

139	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 125-133	5.1	13
138	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 2365-2373	4.9	6
137	A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. <i>Case Reports in Oncological Medicine</i> , <b>2019</b> , 2019, 1018492	0.9	2
136	Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , <b>2019</b> , 71, 181-184	4.4	7
135	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , <b>2019</b> , 10, 5926-5934	4.5	16
134	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , <b>2019</b> , 10, 5903-5914	4.5	8
133	Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 5879616	4.5	17
132	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , <b>2019</b> , 44, 33-38	3.6	52
131	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 192-200	4.6	17
130	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 57-62	8.7	40
129	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , <b>2019</b> , 234, 7708-7717	7	16
128	A multidisciplinary group for prostate cancer management: A single institution experience. <i>Oncology Letters</i> , <b>2018</b> , 15, 1823-1828	2.6	3
127	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 241-252	3.2	4
126	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 474-485	21.7	39
125	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 328-334	4.6	10
124	Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. <i>Cancer</i> , <b>2018</b> , 124, 2923-2930	6.4	24
123	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , <b>2018</b> , 10, 643-655	3.8	9
122	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , <b>2018</b> , 233, 2313-2323	7	17

121	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , <b>2018</b> , 38, 3105-3110	2.3	3
120	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 236	12.8	24
119	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , <b>2018</b> , 10, 1229-1239	3.8	22
118	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <i>Breast</i> , <b>2017</b> , 32, 79-86	3.6	10
117	Body mass index modifies the relationship between $\gamma$ H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 101	4.8	11
116	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients Satisfaction. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 520-525	3.3	7
115	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. <i>Breast</i> , <b>2017</b> , 35, 218-219	3.6	6
114	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. <i>Journal of Human Genetics</i> , <b>2017</b> , 62, 379-387	4.3	0
113	Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 3007-3015	4.4	14
112	Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study. <i>BMC Cancer</i> , <b>2017</b> , 17, 753	4.8	18
111	Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report. <i>International Medical Case Reports Journal</i> , <b>2017</b> , 10, 173-175	1	1
110	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , <b>2017</b> , 8, 54528-54536	3.3	10
109	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , <b>2017</b> , 7, 10597	4.9	11
108	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 1571-1578	7.1578	12
107	"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. <i>Oncotarget</i> , <b>2017</b> , 8, 23891-23904	3.3	17
106	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. <i>Oncotarget</i> , <b>2017</b> , 8, 69025-69037	3.3	6
105	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , <b>2017</b> , 8, 56921-56931	3.3	41
104	Interleukin-30 Promotes Breast Cancer Growth and Progression. <i>Cancer Research</i> , <b>2016</b> , 76, 6218-6229	10.1	27

103	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 986-91	7	11
102	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 62	12.8	19
101	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 21259-71	3.3	14
100	"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , <b>2016</b> , 7, 17932-44	3.3	26
99	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , <b>2016</b> , 7, 19738-47	3.3	106
98	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , <b>2016</b> , 7, 35803-35812	3.3	6
97	CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e21009-e21009	2.2	
96	Treatment of Metastatic Colorectal Cancer Patients ≥5 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157751	3.7	14
95	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1160187	7.2	24
94	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 1327-36	5.2	58
93	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 107, 20-32	7	24
92	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. <i>Breast</i> , <b>2016</b> , 29, 96-101	3.6	16
91	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , <b>2016</b> , 231, 2541-7	7	10
90	Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. <i>Clinical Breast Cancer</i> , <b>2015</b> , 15, e131-7	3	21
89	Rivaroxaban for cancer-associated cardiac thrombosis. <i>American Journal of Medicine</i> , <b>2015</b> , 128, e43-4	2.4	6
88	Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review. <i>Journal of Cancer</i> , <b>2015</b> , 6, 575-82	4.5	4
87	What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. <i>Oncotarget</i> , <b>2015</b> , 6, 35589-601	3.3	49
86	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1704-9	4.6	5

85	Triple positive breast cancer: a distinct subtype?. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 69-76	14.4	56
84	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 31604-12	3.3	27
83	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , <b>2015</b> , 6, 42773-80	3.3	13
82	Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A retrospective multicenter observational study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e11542-e11542	2.2	
81	Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1575-82	3.1	10
80	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. <i>Tumori</i> , <b>2014</b> , 100, e309-e313	1.7	
79	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 599-607	4.4	32
78	Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 916-25	6.1	14
77	Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. <i>PLoS ONE</i> , <b>2014</b> , 9, e94063	3.3	6
76	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , <b>2014</b> , 5, 9619-23	3.3	30
75	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥5 years (y) old in clinical practice: A multicenter analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14514-e14514	2.2	
74	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 1229-40	4.9	6
73	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. <i>Cancers</i> , <b>2013</b> , 5, 919-42	6.6	30
72	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 89	12.8	8
71	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , <b>2013</b> , 91, 83-94	5.5	45
70	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 269-80	4.9	16
69	Tumor-derived microvesicles: the metastasomes. <i>Medical Hypotheses</i> , <b>2013</b> , 80, 75-82	3.8	19
68	Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer. <i>Disease Markers</i> , <b>2013</b> , 35, 747-52	3.2	6

67	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. <i>Journal of Oncology Pharmacy Practice</i> , <b>2013</b> , 19, 246-53	1.7	8
66	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2012</b> , 138, 221-9	4.9	29
65	Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 229-37	3.8	18
64	An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. <i>Current Cancer Drug Targets</i> , <b>2012</b> , 12, 439-52	2.8	24
63	Unknown primary tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2011</b> , 1816, 13-24	11.2	15
62	Tyrosine kinase inhibitors. <i>Current Cancer Drug Targets</i> , <b>2010</b> , 10, 462-83	2.8	33
61	Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2009</b> , 1795, 62-81	11.2	23
60	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 333-8	7.5	22
59	Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. <i>Anticancer Research</i> , <b>2009</b> , 29, 403-10	2.3	41
58	Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. <i>Cancer Letters</i> , <b>2008</b> , 270, 229-33	9.9	40
57	A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1015-20	10.3	11
56	Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1501-6	12.9	22
55	Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 618-20	8.7	3
54	Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 187-90	4.3	15
53	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. <i>Journal of Pathology</i> , <b>2002</b> , 197, 218-23	9.4	21
52	90K (Mac-2 BP) and galectins in tumor progression and metastasis. <i>Glycoconjugate Journal</i> , <b>2002</b> , 19, 551-6	3	122
51	Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3850-6	2.2	34
50	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. <i>Trends in Immunology</i> , <b>2002</b> , 23, 313-20	14.4	45 <sup>o</sup>

49	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. <i>Aids</i> , <b>2000</b> , 14, F41-5	3.5	4
48	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties <b>2000</b> , 85, 545-554		150
47	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , <b>2000</b> , 96, 3282-3285		31
46	Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. <i>FEBS Letters</i> , <b>2000</b> , 473, 311-5	3.8	106
45	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , <b>2000</b> , 96, 3282-3285		2
44	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties <b>2000</b> , 85, 545		10
43	Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections. <i>Clinical and Experimental Immunology</i> , <b>1999</b> , 115, 91-4	6.2	28
42	Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>1999</b> , 4, 151-62	5.4	8
41	Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. <i>Journal of Clinical Immunology</i> , <b>1999</b> , 19, 143-7	5.7	5
40	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , <b>1999</b> , 44, 1013-9	4	11
39	Cyclooxygenase-independent induction of p21WAF-1/CIP1, apoptosis and differentiation by L-745,337 and salicylate in HT-29 colon cancer cells. <i>Advances in Experimental Medicine and Biology</i> , <b>1999</b> , 469, 555-61	3.6	3
38	90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. <i>International Journal of Cancer</i> , <b>1998</b> , 79, 23-6	7.5	25
37	Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. <i>Clinical and Experimental Immunology</i> , <b>1998</b> , 113, 394-400	6.2	17
36	Prognostic value of a novel interferon-inducible 90K tumor antigen. <i>Annals of the New York Academy of Sciences</i> , <b>1996</b> , 784, 288-93	6.5	6
35	Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. <i>Cancer Letters</i> , <b>1996</b> , 107, 143-8	8.9	11
34	The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 225, 617-20	3.4	21
33	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 212-7	13.4	72
32	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. <i>International Journal of Cancer</i> , <b>1996</b> , 68, 34-8	7.5	29



31	90K (Mac-2 BP) in human milk. <i>Clinical and Experimental Immunology</i> , <b>1996</b> , 104, 543-6	6.2	35
30	The 90K tumor-associated antigen and clinical progression in human immunodeficiency virus infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1995</b> , 10, 450-6		14
29	A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1995</b> , 18, 27-31	2.7	6
28	Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen. <i>International Journal of Cancer</i> , <b>1995</b> , 64, 130-4	7.5	10
27	Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus. <i>Journal of Infection</i> , <b>1994</b> , 28, 31-9	18.9	6
26	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. <i>International Journal of Cancer</i> , <b>1994</b> , 59, 808-13	7.5	21
25	Prognostic value of a novel circulating serum 90K antigen in breast cancer. <i>British Journal of Cancer</i> , <b>1994</b> , 69, 172-6	8.7	107
24	90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. <i>Oncology Reports</i> , <b>1994</b> , 1, 723-5	3.5	8
23	A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. <i>AIDS Research and Human Retroviruses</i> , <b>1993</b> , 9, 811-6	1.6	27
22	DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. <i>Cancer</i> , <b>1993</b> , 71, 1289-96	6.4	28
21	Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. <i>British Journal of Cancer</i> , <b>1993</b> , 67, 564-7	8.7	22
20	Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. <i>British Journal of Haematology</i> , <b>1993</b> , 85, 207-9	4.5	17
19	Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. <i>FEBS Letters</i> , <b>1993</b> , 319, 59-65	3.8	41
18	Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. <i>British Journal of Cancer</i> , <b>1992</b> , 66, 981-3	8.7	5
17	DNA ploidy and S-phase fraction in pulmonary carcinoids. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1933-4	7.5	2
16	Combinations of biological response modifiers: rationale and clinical responses. <i>Pharmacological Research</i> , <b>1992</b> , 26 Suppl 2, 102-3	10.2	
15	Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. <i>Journal of Infectious Diseases</i> , <b>1991</b> , 164, 819	7	17
14	Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. <i>Journal of Infectious Diseases</i> , <b>1991</b> , 164, 616-7	7	22

13	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. <i>Cancer</i> , <b>1990</b> , 65, 1325-8	6.4	8
12	Recombinant human leukocyte interferon-alpha 2b stimulates the synthesis and release of a 90K tumor-associated antigen in human breast cancer cells. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 182-4	7.5	30
11	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>1988</b> , 11, 19-30	4.4	45
10	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: evidence for differential mechanism of action on tumor cells in vitro. <i>Breast Cancer Research and Treatment</i> , <b>1985</b> , 6, 255-6	4.4	4
9	Hormone-modulated rRNA gene activity is visualized by selective staining of the NOs. <i>Cell Biology International Reports</i> , <b>1985</b> , 9, 791-6		50
8	Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , <b>1984</b> , 20, 747-52		10
7	Tamoxifen induced membrane alterations in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , <b>1984</b> , 20, 425-8		14
6	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. <i>Breast Cancer Research and Treatment</i> , <b>1983</b> , 3, 23-32	4.4	38
5	Growth inhibitory effects of thyroid hormones on androgen-dependent mammary tumor cells. <i>The Journal of Steroid Biochemistry</i> , <b>1981</b> , 15, 409-13		3
4	Effect of thyroid hormones on androgen responsiveness in a mammary tumor cell line. <i>The Journal of Steroid Biochemistry</i> , <b>1981</b> , 15, 415-9		1
3	Glucocorticoids inhibit the stimulatory effect of epidermal growth factor on the initiation of DNA synthesis. <i>Journal of Cellular Physiology</i> , <b>1981</b> , 107, 155-63	7	24
2	Estrogen binding by neoplastic human thymus cytosol. <i>European Journal of Cancer</i> , <b>1980</b> , 16, 951-5		25
1	Gynaecomastia with cimetidine. <i>Lancet, The</i> , <b>1977</b> , 1, 1319	40	69